Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
237.72
+7.70 (3.35%)
Jun 29, 2026, 4:00 PM EDT - Market closed

Jazz Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $257. The average 1-year stock price forecast is 8.11% higher than the current stock price, while the lowest is $196 (-17.55%) and the highest is $307 (+29.14%).

Price Target: $257 (+8.11%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$196$257$255$307
Change-17.55%+8.11%+7.27%+29.14%

Analyst Ratings

The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy109991010
Buy555677
Hold122211
Sell000011
Strong Sell000000
Total161616171919

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Truist Financial
Truist Financial
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 18, 2026
Unknown Analyst
Jefferies
No rating
Jefferies
Buy
Maintains
$265
BuyMaintains$265+11.48%Jun 16, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$301
BuyReiterates$301+26.62%Jun 16, 2026
TD Cowen
TD Cowen
Buy
Maintains
$275
BuyMaintains$275+15.68%Jun 12, 2026
Bank of America Securities
Bank of America Securities
Buy
Reiterates
$307
BuyReiterates$307+29.14%Jun 10, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
4.51B
from 4.27B
Increased by 5.79%
Revenue Next Year
4.84B
from 4.51B
Increased by 7.18%
EPS This Year
25.39
from 8.38
Increased by 202.97%
EPS Next Year
25.61
from 25.39
Increased by 0.88%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.09B3.66B3.83B4.07B4.27B4.51B
Revenue Growth
30.91%18.26%4.78%6.12%4.88%5.79%
Gross Profit
2.88B3.39B3.55B3.76B3.91B4.05B
Gross Margin
92.97%92.70%92.59%92.36%91.67%89.76%
Operating Income
475.26M839.14M816.23M864.14M1.02B2.05B
Net Income
-329.67M-224.06M414.83M560.12M-356.15M960.94M
EPS
----8.3825.39
EPS Growth
-----59.90%202.97%
Forward PE
8.238.546.295.727.679.36
Free Cash Flow
-138.27M1.12B1.06B1.44B1.35B1.38B
No. Analysts
-----18
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High4.8B
Avg4.5B
Low4.4B

Revenue Growth

Revenue Growth202620272028
High
11.5%
Avg
5.8%
Low
3.0%

EPS Forecast

EPS202620272028
High27.51
Avg25.39
Low24.38

EPS Growth

EPS Growth202620272028
High
228.3%
Avg
203.0%
Low
190.9%